ANI Pharma's eye implant meets main goals in eye disease trial
ANIP•Safety results and next steps
Iluvien releases a low dose of steroid inside the eye for up to three years.
Most common treatment-related side effects were increased eye pressure (6%) and cataracts (5%), with 29% of patients reporting treatment-related side effects.
Co plans to present detailed study results at medical meetings later this year.
As of last close, stock up 4% YTD.
Follow-up study met both main goals
Drugmaker ANI Pharmaceuticals ANIP.O says its implant met both main goals in a follow-up study in chronic non-infectious uveitis, a recurring inflammatory eye disease that can cause vision loss.
Trial showed patients gained an average of 3.6 letters in visual acuity, a measure of eyesight, after six months of treatment with Iluvien.
ANI says it also significantly reduced retinal swelling, meeting the study's other main goal.
